CalciMedica, Inc. (NASDAQ:CALC) Sees Significant Growth in Short Interest

CalciMedica, Inc. (NASDAQ:CALC) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 93,300 shares, an increase of 35.0% from the January 31st total of 69,100 shares. Approximately 1.3% of the shares of the company are sold short. Based on an average daily volume of 40,600 shares, the short-interest ratio is presently 2.3 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of CalciMedica in a research note on Tuesday.

CalciMedica Stock Performance

Shares of CALC traded down $0.08 during midday trading on Wednesday, hitting $2.19. 2,085 shares of the stock traded hands, compared to its average volume of 41,390. CalciMedica has a 1-year low of $1.86 and a 1-year high of $6.27. The business’s 50 day moving average price is $2.78 and its two-hundred day moving average price is $3.46. The firm has a market capitalization of $29.53 million, a PE ratio of -1.90 and a beta of 1.20.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Cetera Investment Advisers boosted its position in shares of CalciMedica by 37.1% during the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after buying an additional 4,566 shares during the period. PVG Asset Management Corp bought a new stake in CalciMedica during the 3rd quarter valued at $67,000. Atria Investments Inc boosted its position in CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after acquiring an additional 15,296 shares during the period. Corient Private Wealth LLC bought a new position in shares of CalciMedica in the fourth quarter worth $135,000. Finally, Renaissance Technologies LLC acquired a new position in shares of CalciMedica during the fourth quarter valued at $153,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.